A new discovery about how cells communicate with each other in the body's immune system has revealed deeper insights for an ...
PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative ColitisCarlsbad, CA, ...
AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient ...
Forensic audit using advanced AI reveals the objective logic of the soul, offering a user manual for consciousness ...
Presenter: Michael Gazda, Ph.D. The abstracts are scheduled to be posted to the ASCO GI Online Program at 5 PM ET on Monday, January 6. About BXQ-350 Bexion's lead drug candidate is BXQ-350, a ...
Poster presenters will be assigned to a 1-hour poster session where they will discuss their research with interested attendees at the APS Annual Convention. Poster sessions are scheduled on all days ...
– Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% Compared to Placebo – – An Exploratory Analysis of CLEAR ...
Nearly eight months after Kanzi, the celebrated bonobo at Des Moines’ Ape Cognition and Conservation Initiative, died more than 150 people came together to honor his life and legacy. The gathering, ...
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced ...
Company studies continue to show durability and retention of benefits for patients receiving proximal hypoglossal nerve stimulation for moderate to severe obstructive sleep apnea LivaNova PLC (Nasdaq: ...
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its participation in the International Surgical Sleep Society (ISSS) 2025 Annual Meeting in Indianapolis. The ...
Company studies continue to show durability and retention of benefits for patients receiving proximal hypoglossal nerve stimulation for moderate to severe obstructive sleep apnea “Nearly 2 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback